ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys-Reference-Cited by-同舟云学术

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys

Published:2015-07 Issue:7 Volume:56 Page:1308-1317
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Gusarova Viktoria,Alexa Corey A.,Wang Yan,Rafique Ashique,Kim Jee Hae,Buckler David,Mintah Ivory J.,Shihanian Lisa M.,Cohen Jonathan C.,Hobbs Helen H.,Xin Yurong,Valenzuela David M.,Murphy Andrew J.,Yancopoulos George D.,Gromada Jesper

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference38 articles.

1. Lipoprotein lipase: genetics, lipid uptake, and regulation;Merkel;J. Lipid Res.,2002

2. Lipoprotein lipase: from gene to obesity;Wang;Am. J. Physiol. Endocrinol. Metab.,2009

3. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase;Shimizugawa;J. Biol. Chem.,2002

4. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo;Ono;J. Biol. Chem.,2003

5. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism;Köster;Endocrinology.,2005

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evinacumab: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-06

2. Triglyceride-rich lipoproteins and cardiovascular diseases;Frontiers in Endocrinology;2024-05-31

3. Evaluating the Effectiveness and Safety of Evinacumab in Treating Hypercholesterolemia and Hypertriglyceridemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials;American Journal of Cardiovascular Drugs;2024-05-07

4. Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk;European Heart Journal Open;2024-04-30

5. Management of dyslipidemia in coronary artery disease: the present and the future;Coronary Artery Disease;2024-04-29